ATP5MPL

Across TCGA pan-cancer cohorts, ATP5MPL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP5MPL data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP5MPL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5MPL expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where ATP5MPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.167	0.664	<.001	20	view →
UCEC	OS	Tertile	III,IV	0.855	0.520	.046	4	view →
CCRCC	DFS	Quartile	III,IV	0.074	0.740	.038	3	view →
HNSC	DFS	Quartile	III,IV	0.825	0.471	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP5MPL–LUAD (DFS)

Open the LUAD breakdown →